Answers are grounded in this paper and cite their sources.
Mesenchymal stem cells (MSCs) hold notable therapeutic potential for pneumonia, yet their intravenous administration is limited by pulmonary homing, in which the majority of infused cells become trapped in the lung microvasculature due to their size. Historically considered an embolic hazard and a barrier to systemic delivery, this phenomenon may instead be advantageous when the lung is the intended therapeutic target. The present review reframes pulmonary homing as a potential therapeutic delivery advantage for pneumonia treatment and summarizes the updated consensus criteria for defining MSCs and compares the key features of mesodermal‑ vs. ectodermal‑derived MSC populations. How MSCs temper pneumonia‑associated cytokine storms by modulating macrophage pyroptosis, neutrophil extracellular trap formation and natural killer cell activity is also examined. Finally, the mechanisms that drive pulmonary entrapment are reviewed and the balance between therapeutic benefit and embolic risk is considered. Reinterpreting a long‑perceived liability as a therapeutic asset relies on a detailed understanding of the biophysical and molecular determinants that govern MSC retention in the lung.
No takes yet. Share an insight, caveat, or question.
Suo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: